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The development of solid tumors is regulated by dynamic interactions between evolving 
neoplastic cells and their microenvironment. Luo et al. (2007) recently demonstrated that tumor-
infiltrating immune cells expressing RANKL induce activation and nuclear localization of IKKα 
in prostatic epithelial tumor cells. This leads to repression of maspin, a critical suppressor of 
metastasis, and thus commits malignant prostatic epithelial cells to a metastatic fate.Clinical evidence for a causative link 
between chronic inflammation and 
cancer has come from epidemiologi-
cal studies. These studies reported 
that inhibiting chronic inflammation in 
patients with premalignant disease, 
or who are predisposed to cancer 
development, reduces cancer risk 
and/or cancer recurrence (for review 
see Thun et al., 2002). Molecular 
mechanisms linking inflammation and 
development of epithelial cancer have 
only recently been provided by utili-
zation of sophisticated in vivo molec-
ular methodologies, in combination 
with immune-competent mouse 
models of multistage carcinogenesis 
(reviewed in de Visser et al., 2006 and 
Karin, 2006). These have revealed the 
significance of the transcription fac-
tor nuclear factor κB (NFκB) and its 
activating IκB kinases (IKKα and β) 
in cancer progression via their ability 
to differentially regulate cell survival 
and production of proinflammatory 
cytokines. According to Luo et al. 
(2007), as recently reported in Nature, 
IKKα also promotes metastasis.
Using a transgenic mouse model 
of prostate cancer in which the 
SV40 large T antigen is selectively 
expressed in prostate epithelium 
(TRAMP mice), Luo and colleagues 
(2007) have identified IKKα as a key 
mediator of the interplay between 
inflammation and metastasis in pros-
tate cancer. To address the functional significance of IKKα, TRAMP mice 
were crossed with mice harboring an 
inactive IKKα (IKKαAA/AA/TRAMP). In 
these mice both the onset of tumors 
and mortality were delayed, whereas 
the histopathology and size of the 
primary tumor was not changed 
compared to mice with wild-type 
IKKα. Instead, IKKαAA/AA/TRAMP 
mice developed significantly fewer 
metastases in distant organs. This 
effect was associated with sustained 
expression levels of the metastasis 
suppressor maspin (mammary serine 
protease inhibitor).
Maspin was first identified as a 
putative suppressor of metastasis by 
virtue of its high level of expression 
in normal mammary epithelial cells 
as compared to its greatly reduced or 
absent expression in malignant cells 
(reviewed in Sheng, 2004). Due to its 
structural homology to serine pro-
tease inhibitors (serpins), maspin was 
initially thought to regulate metasta-
sis via inhibition of serine proteases 
involved in regulating cell-cell and/or 
cell-extracellular matrix interactions. 
However, it was later determined that 
maspin did not inhibit trypsin-like 
serine proteases, providing compel-
ling evidence that maspin, unlike 
other serpins, was not a classical 
serine protease inhibitor. More recent 
investigations revealed that maspin 
regulates metastasis, in part, by 
altering integrin profiles associated Cell 1with increased cellular adherence 
to fibronectin, thus reducing ability 
of cells to move through fibronectin 
matrices. Although maspin displays 
antimetastatic properties during 
mammary and prostate cancer devel-
opment, its expression is maintained 
during ovarian, lung, and pancre-
atic carcinogenesis, indicating that 
maspin-regulated metastatic poten-
tial is tissue specific.
Loss of maspin expression dur-
ing tumor progression was demon-
strated to result, in part, from absent 
Ets and Ap1 transactivation in com-
bination with epigenetic silencing by 
methylation (Sato et al., 2004). Luo 
and colleagues (2007) now provide 
evidence that prior to silencing by 
methylation, the maspin promoter 
is transiently repressed by IKKα, 
which is phosphorylated in response 
to RANKL (receptor activator of 
NFκB ligand) binding to its receptor 
RANK. Furthermore, this function of 
IKKα is shown to be independent of 
NFκB. It remains to be determined if 
IKKα-mediated repression of maspin 
expression involves Ets and/or Ap1.
RANKL is a membrane-bound pro-
tein belonging to the tumor necro-
sis factor (TNF)-α family of ligands. 
Thus, activation of its receptor RANK 
requires close contact between cells 
or proteolytic cleavage of the RANKL 
extracellular domain. Prostate cancer 
cells are known to express and secrete 29, April 6, 2007 ©2007 Elsevier Inc. 25
figure 1. IKKα and Maspin in Prostate Cancer Metastasis
The metastasis suppressor gene maspin is highly expressed in early prostate tumor cells. Fol-
lowing infiltration of RANKL-producing immune cells, RANK phosphorylates and activates IKKα, 
inducing its nuclear translocation and interaction with the maspin promoter causing its transient 
repression. This gene is then silenced by methylation, committing prostate cancers to a meta-
static fate. Activation of RANK on prostate cancer cells requires either close contact with RANKL-
expressing immune cells, cleavage of the RANKL extracellular domain by proteases such as 
MMP-7, or alternatively, immune cell expression of a secreted form of RANKL.soluble RANKL (sRANKL) (Zhang et 
al., 2001); RANKL is also expressed 
by lymphoid and myeloid cells; thus, 
as immune cells are recruited to sites 
of neoplastic growth, local levels 
of RANKL increase. The observa-
tions presented by Luo et al. (2007) 
demonstrate that in primary pros-
tate cancers, it is indeed infiltrating T 
lymphocytes and macrophages that 
express RANKL. Whether these infil-
trating cells express soluble RANKL 
or how membrane-associated RANKL 
is activated remain undetermined.
The ability of macrophages to 
promote tumorigenesis has been 
previously reported using a mouse 
model of mammary carcinogenesis, 
in which infiltration of macrophages 
into premalignant mammary tissue 
is associated with primary tumor 
progression (Lin et al., 2006 and 
references therein). Depletion of 
or failure to recruit macrophages 
into neoplastic tissue does not sig-
nificantly alter hallmarks of prema-
lignancy but instead significantly 
delays development of invasive car-
cinomas (likely through regulation 
of angiogenesis) and reduces the 
formation of pulmonary metastasis 
(Lin et al., 2006). This indicates that 
molecules secreted by tissue mac-
rophages, in addition to enhanc-
ing primary tumor development via 
pro-angiogenic mechanisms, also 
mediate metastatic progression of 26 Cell 129, April 6, 2007 ©2007 Elseviemammary tumors. Studies by Luo 
et al. (2007) now provide a new 
mechanism for the promotion of 
metastasis in which recruited mac-
rophages secrete the proinflamma-
tory cytokine RANKL. This binds 
RANK and leads to the phospho-
rylation of IKKα to induce repres-
sion of maspin in malignant epithe-
lial cells, therefore enhancing their 
metastasis (Figure 1). Interestingly, 
IKKβ does not possess similar abil-
ity to promote metastasis in pros-
tate cancer. This is surprising given 
that it confers survival signals to 
enterocytes enabling them to evade 
apoptotic elimination. IKKβ also 
induces the production of proin-
flammatory cytokines by myeloid 
cells that act as paracrine growth 
factors for the premalignant ente-
rocytes (reviewed in Karin, 2006). 
Taken together, these reports high-
light the significance of IKK family 
members as important regulators 
of not only cancer initiation and 
promotion but now also metastasis 
and offer insights into potential new 
therapeutic targets for treatment of 
metastatic disease, namely RANKL/
RANK, IKKα, and maspin.
Maspin is an intriguing candidate 
for new therapies. Indeed, demeth-
ylation of the maspin promoter ena-
bling maspin re-expression in malig-
nant cells could represent a viable 
approach to inhibit metastasis of r Inc.malignant prostatic epithelial cells 
and/or stabilize primary disease. 
Reactivation of maspin expression 
could be achieved by use of DNA 
methylation inhibitors such as 5-
aza-2′-deoxycytidine or inhibitors 
of DNA methyltransferase, includ-
ing specific DNA methyltransferase 
hairpin antagonists. Alternatively, 
because these agents lack specifi-
city, RANKL/RANK or IKKα antago-
nists could prove useful as they might 
not only diminish prostate cancer 
metastasis but would also reduce the 
bone-degrading activity of metastatic 
prostate cancer cells that is associ-
ated with RANKL signaling. It is inter-
esting to speculate that the efficacy 
of pyrophosphate analogs, such as 
bisphosphonates, known to reduce 
osteolysis associated with prostate 
cancer (Clezardin et al., 2005), may 
be due in part to regulating RANKL/
RANK, IKKα, or maspin bioactivity 
in malignant tumor cells and/or in 
infiltrating immune cells. Thus, taken 
together, identification of this impor-
tant new pathway by Luo et al. (2007) 
offers insight into how immune cells 
affect metastasis and reveals several 
new potential targets for anticancer 
therapy.
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